ATG5 as a Serum Marker of Autophagy in Psoriatic Patient | NCT05279638

Studies
ATG5 as a Serum Marker of Autophagy in Psoriatic Patient

NCT05279638

Sponsor

Sohag University

Status

Unknown status

Last Update Posted

Mar 15, 2022Actual

Enrollment

90Estimated

Phase

Not provided

Conditions

Psoriasis Vulgaris
Autophagy

Interventions

serum ATG5

Countries

Egypt

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

Annotation Module

Unposted Annotation

Unposted Responsible Party

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Mar 2022

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Feb 1, 2022Actual

Primary Completion Date

Feb 1, 2023Estimated

Completion Date

Jan 1, 2024Estimated

First Submitted Date

Feb 23, 2022

First Submission Date that Met QC Criteria

Mar 6, 2022

First Posted Date

Mar 15, 2022Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Mar 6, 2022

Last Update Posted Date

Mar 15, 2022Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

it will be of interest to know the ATG 5 as a serum marker of autophagy in serum of psoriasis vulgairs patients and explore its relationship with psoriasis severity.

Detailed Description

Not provided

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

90Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
psoriasis vulgaris patients		psoriasis vulgaris patients , both sex , 18,55 years old	Diagnostic Test: serum ATG5
healthy participants			Diagnostic Test: serum ATG5

Interventions

Name	Type	Description	Arm Group Labels	Other Names
serum ATG5	Diagnostic Test	This kit is used to assay the Autophagy protein 5(ATG5) in the sample of human's serum, blood plasma, and other related tissue Liquid	healthy participants

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
serum level of ATG5 in psoriatic patients	evaluation of serum ATG5 in psoriasis vulgaris patients by ELISA	Within 6 months

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Psoriasis vulgaris of both sex, age 18-55 years

Exclusion Criteria:

i. Patients with other types of psoriasis ii. Pregnant or lactating women iii. patients with hepatic or renal diseases iv. patients receive any systemic treatment in last 3 months

Accepts Healthy Volunteers

Yes

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

55 Years

Standard Ages

Adult

Study Population

Patients with psoriasis vulgaris and healthy participatins

Sampling Method

Probability Sample

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Ayatallah Hamdi Abdelrahmim	Contact	01005482447		ayatallah_hamdy_post@med.sohag.edu.eg

Overall Officials

Not provided

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Sohag University	Recruiting	Sohag			Egypt

IPD Sharing Statement Module

Plan to Share IPD

Undecided

Description

Not provided

Types

Not provided

Time Frame

Not provided

Access Criteria

Not provided

URL

Not provided

Type	Date	Date Unknown
Release	Dec 19, 2023
Reset	Jun 14, 2024

Submission Tracking

Estimated Results First Submitted Date

Dec 19, 2023

First MCP Posted Date

Not provided

Submission Infos

Release Date	Unrelease Date	Unrelease Date Unknown	Reset Date	MCP Release Number
Dec 19, 2023			Jun 14, 2024